Piroxicam
- Generic Name
- Piroxicam
- Brand Names
- Feldene
- Drug Type
- Small Molecule
- Chemical Formula
- C15H13N3O4S
- CAS Number
- 36322-90-4
- Unique Ingredient Identifier
- 13T4O6VMAM
- Background
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
- Indication
For treatment of osteoarthritis and rheumatoid arthritis.
- Associated Conditions
- Ankylosing Spondylitis (AS), Osteoarthritis (OA), Rheumatoid Arthritis
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception
- Conditions
- Emergency Contraception
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Dr. Hang Wun Raymond Li
- Target Recruit Count
- 860
- Registration Number
- NCT03614494
- Locations
- 🇭🇰
The Family Planning Association of Hong Kong, Hong Kong, Hong Kong
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
Comparison Between Intraligamentary Piroxicam and Articaine
- Conditions
- Pulpitis - Irreversible
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 20
- Registration Number
- NCT03612323
Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
- Conditions
- PainCytochrome P450 CYP2C9 Enzyme DeficiencyOther Surgical ProceduresImpacted Third Molar Tooth
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 105
- Registration Number
- NCT02450487
Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 1400
- Registration Number
- NCT02304783
- Locations
- 🇹🇳
Emergency Department of University Hospital of Monastir, Monastir, Tunisia
A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Pamukkale University
- Target Recruit Count
- 400
- Registration Number
- NCT02253446
- Locations
- 🇹🇷
Pamukkale Universty, Denizli, Turkey
Effect of Piroxicam on Ovulation
- Conditions
- Contraception, Postcoital
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT01320709
Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Dietary Supplement: Olive Oil
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2010-04-29
- Lead Sponsor
- Ardabil University of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00670475
- Locations
- 🇮🇷
ArdabiUMS clinic of rheumatology, Ardabil, Iran, Islamic Republic of
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT00649415
- Locations
- 🇧🇷
Pfizer Investigational Site, São Paulo, Brazil
Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2008-03-10
- Lead Sponsor
- University Hospital of Split
- Target Recruit Count
- 88
- Registration Number
- NCT00631514
- Locations
- 🇭🇷
Split University School of Medicine. Family Practice Department, Split, Croatia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.